LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

Clinical trial NCT02187783 · COMPLETED

Trial details

NCT number: NCT02187783
Sponsor: Novartis Pharmaceuticals
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Tumors With CDK4/6 Pathway Activation

Start date: 2014-08-25
Primary completion: 2018-01-17
Enrollment: 106

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.